During the preparation of the Company’s financial statements for the three months ended June 30, 2024, due to the decision to close the Company’s Baltimore-Bayview Drug Substance manufacturing facility and the Rockville, Maryland Drug Product facility, the Company determined there were sufficient indicators of impairment for the Bayview and Rockville asset groups within the Bioservices reporting unit. As a result, the Company performed recoverability tests on those asset groups and concluded that the Bayview and Rockville asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values.

Asset groups are written down only to the extent that their carrying value is higher than their respective fair value. The Company, with the assistance of a third-party valuation firm, applied valuation methods to estimate the fair values for each of the assets within the different asset classes. An orderly liquidation value was applied to estimate the fair value of the personal property assets and market and cost based approaches were applied to estimate the fair value of the real property assets, each representing Level 3 non-recurring fair value measurements. Based on these analyses, the Company allocated and recognized a non-cash impairment charge of $27.2 million during the second quarter of 2024.

During the preparation of the Company’s financial statements for the three months ended June 30, 2023, due to deterioration in performance and resulting downward revisions to the Company’s internal Bioservices forecast made during the second quarter, including future expected cash flows, the Company determined there were sufficient indicators of impairment on the Camden, Bayview and Rockville asset groups within the Bioservices reporting unit to require an impairment analysis. As a result, the Company performed recoverability tests on certain asset groups within the Bioservices reporting unit and concluded that the impacted asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values.


	Nine Months Ended September 30, 2024		Nine Months Ended September 30, 2023
Buildings, building improvements and leasehold improvements	7.8		81.5
Furniture and equipment	14.1		117.5
Software	0.2		0.3
Construction-in-progress	5.1		107.4
Total impairment of long-lived assets	$	27.2	$	306.7

In January 2023, the Company initiated an organizational restructuring plan (the “January 2023 Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees. The charges related to the January 2023 plan consist primarily of employee transition, severance payment and employee benefit charges. The cumulative amount of restructuring charge related to the January 2023 Plan since inception is $9.3 million. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company’s classification policy for each category of operating expense.

In August 2023, the Company initiated the August 2023 Plan which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees. The charges related to the August 2023 Plan consist primarily of employee transition, severance payment and employee benefit charges. The cumulative amount of restructuring charge related to the August 2023 Plan since inception is $19.4 million. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company’s classification policy for each category of operating expense.

In May 2024, the Company initiated the May 2024 Plan. These strategic actions led to a reduction of the Company’s workforce by approximately 300 employees across all areas of the Company and the elimination of approximately 85 positions that were vacant, as well as the closure of the Company’s Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. Decisions regarding the elimination of positions and the closure of manufacturing facilities were subject to local law and consultation requirements in certain countries, as well as the Company’s business needs. The cumulative amount of restructuring charge related to the May 2024 Plan since inception is $20.0 million. All activities related to the May 2024 Plan were substantially completed during the third quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.

In August 2024, the Company initiated the August 2024 Plan at the Company’s Lansing facility, which reduced the Company’s workforce by approximately 70 employees, as well as eliminated several open positions. The Company also implemented non-labor optimization efforts, such as reducing the Company’s external and vendor spend. The cumulative amount of restructuring charges related to the August 2024 Plan since inception is $3.5 million. All activities related to the August 2024 Plan are expected to be substantially completed during the fourth quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company’s classification policy for each category of operating expense.

The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by reportable segment as well as amounts included within unallocated corporate selling general and administrative (“SG&A”) expense and research and development (“R&D”) expense:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Commercial Products	$	—	$	—	$	—	$	—
MCM Products	4.9		5.0		7.5		7.0
Services	0.1		8.1		0.3		8.1
Total restructuring costs by segment	5.0		13.1		7.8		15.1
SG&A	0.7		6.3		9.2		11.4
R&D	0.6		0.9		5.9		3.4
Total restructuring costs	$	6.3	$	20.3	$	22.9	$	29.9


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Employee transition	$	0.1	$	0.3	$	0.3	$	0.6
Severance payments	5.0		17.9		19.3		26.6
Employee benefits	1.2		2.1		3.3		2.7
Total restructuring costs	$	6.3	$	20.3	$	22.9	$	29.9


	Employee Transition		Severance Payments		Employee Benefits		Total
Balance at December 31, 2023	$	—	$	1.4	$	—	$	1.4

Cash payments	—		(1.3)		—		(1.3)
Balance at March 31, 2024	$	—	$	0.1	$	—	$	0.1

Cash payments	—		(0.1)		—		(0.1)
Balance at June 30, 2024	$	—	$	—	$	—	$	—
Accruals	—		—		—		—
Cash payments	—		—		—		—
Balance at September 30, 2024	$	—	$	—	$	—	$	—


	Employee Transition		Severance Payments		Employee Benefits		Total
Balance at December 31, 2022	$	—	$	—	$	—	$	—
Accruals	0.3		8.7		0.7		9.7
Cash payments	(0.2)		(2.0)		(0.1)		(2.3)
Balance at March 31, 2023	$	0.1	$	6.7	$	0.6	$	7.4
Accruals	—		0.1		(0.2)		(0.1)
Cash payments	—		(3.6)		(0.1)		(3.7)
Balance at June 30, 2023	$	0.1	$	3.2	$	0.3	$	3.6
Accruals	—		—		(0.2)		(0.2)
Cash payments	—		(1.1)		—		(1.1)
Balance at September 30, 2023	$	0.1	$	2.1	$	0.1	$	2.3


	Employee Transition		Severance Payments		Employee Benefits		Total
Balance at December 31, 2023	$	—	$	5.3	$	0.1	$	5.4
Accruals	—		(0.5)		—		(0.5)
Cash payments	—		(3.6)		—		(3.6)
Balance at March 31, 2024	$	—	$	1.2	$	0.1	$	1.3
Accruals	—		(0.1)		—		(0.1)
Cash payments	—		(0.5)		(0.1)		(0.6)
Balance at June 30, 2024	$	—	$	0.6	$	—	$	0.6
Accruals	—		—		—		—
Cash payments	—		(0.3)		—		(0.3)
Balance at September 30, 2024	$	—	$	0.3	$	—	$	0.3


	Employee Transition		Severance Payments		Employee Benefits		Total
Balance at June 30, 2023	$	—	$	—	$	—	$	—
Accruals	0.3		17.9		2.3		20.5
Cash payments	(0.2)		(1.7)				(1.9)
Balance at September 30, 2023	$	0.1	$	16.2	$	2.3	$	18.6


	Employee Transition		Severance Payments		Employee Benefits		Total
Balance at March 31, 2024	$	—	$	—	$	—	$	—
Accruals	0.2		14.8		2.2		17.2
Cash payments	(0.2)		—		—		(0.2)
Balance at June 30, 2024	$	—	$	14.8	$	2.2	$	17.0
Accruals	—		2.3		0.5		2.8
Cash payments	—		(6.3)		(0.7)		(7.0)
Balance at September 30, 2024	$	—	$	10.8	$	2.0	$	12.8


	Employee Transition		Severance Payments		Employee Benefits		Total
Balance at June 30, 2024	$	—	$	—	$	—	$	—
Accruals	0.1		2.7		0.7		3.5
Cash payments	(0.1)		—		—		(0.1)
Balance at September 30, 2024	$	—	$	2.7	$	0.7	$	3.4